Blocking the Pain Peptide Substance P Protects the Brain After Traumatic Injury in Mice | Research

The takeaway

Both blocking substance P's receptor and genetically removing substance P protected against brain damage, memory loss, and inflammation after traumatic brain injury in mice.

Dual validation: drug + genetic deletion
Both pharmacological blockade (NK1R antagonist) and genetic removal of substance P produced neuroprotection, providing strong convergent evidence that substance P drives secondary brain damage after TBI.

What the researchers found

Both pharmacological blockade of substance P's receptor (NK1R antagonist L-733,060) and genetic deletion of substance P provided significant neuroprotection after traumatic brain injury in mice. Both approaches reduced motor and memory deficits, lesion volume, brain swelling, and blood-brain barrier disruption. The protective mechanisms involved inhibition of mitochondrial cytochrome c release, caspase-3 activation (cell death), oxidative stress, and neuroinflammation. TBI increased substance P levels in serum and cortex and upregulated NK1R expression, with NK1R upregulation occurring independent of substance P levels.

Why it matters

Traumatic brain injury affects millions yearly with no approved neuroprotective drug treatments. This study identifies substance P — a well-characterized neuropeptide — as a therapeutic target for TBI. Since NK1R antagonists (substance P receptor blockers) already exist as approved drugs for other conditions (like aprepitant for nausea), repurposing them for TBI could accelerate clinical translation.

The numbers in context

Wild type + SP knockout mice · controlled cortical impact model · reduced motor deficits · reduced spatial memory deficits · reduced lesion volume · reduced brain water content · reduced BBB disruption · inhibited caspase-3 · reduced ROS production

How the study worked

Adult male C57BL/6J wild-type mice and substance P knockout (SPKO) mice received controlled cortical impact TBI. Wild-type mice were treated with NK1R antagonist L-733,060 or vehicle. Outcomes included motor function, spatial memory, lesion volume, brain water content, blood-brain barrier permeability, and molecular markers of cell death (cytochrome c, caspase-3), oxidative stress, and neuroinflammation. In vitro scratch injury models complemented the in vivo findings.

Who was studied

Adult male C57BL/6J wild-type and substance P knockout mice with controlled cortical impact TBI

What this study cannot tell us

This is a preclinical mouse study, and TBI in mice may not fully recapitulate human brain injury pathology. The controlled cortical impact model represents only one type of TBI. Long-term functional outcomes beyond the acute phase were not reported. The optimal therapeutic window for NK1R antagonist administration after TBI was not established. The drug L-733,060 is a research compound, not a clinically available NK1R antagonist.

How to read the evidence

This is a well-designed preclinical study using complementary approaches (pharmacological and genetic) with both in vivo and in vitro validation. The convergent evidence is strong, but clinical translation requires human studies.

When this study was published

Published in 2019, this study contributes to growing evidence for substance P's role in brain injury. Research into NK1R antagonists for neuroprotection continues to develop.

The bigger picture

Despite decades of research, no drug has been approved to protect the brain after TBI. Substance P represents a compelling target because its biology is well understood, receptor antagonists already exist, and the peptide's harmful role has been documented across multiple neurological conditions. This study adds TBI to the list of conditions where targeting substance P could be beneficial, joining ongoing research in pain, depression, and neuroinflammation.

Questions still open

Would clinically available NK1R antagonists like aprepitant (Emend) provide similar neuroprotection after TBI?
What is the therapeutic time window — how long after TBI can NK1R blockade still provide meaningful neuroprotection?
Does substance P's role in TBI differ between mild concussion and severe traumatic brain injury?

Common questions

Why does substance P make brain injury worse?

After a head injury, substance P is released in the brain where it triggers inflammation, weakens the blood-brain barrier (allowing harmful substances to enter brain tissue), promotes oxidative stress (damaging cells with free radicals), and activates cell death pathways. Essentially, this peptide amplifies the 'secondary injury' cascade that continues damaging the brain hours and days after the initial trauma.

Could existing substance P-blocking drugs be used for brain injury patients?

Potentially. NK1R antagonists like aprepitant (Emend) are already FDA-approved for preventing chemotherapy-induced nausea and vomiting. If future studies confirm that blocking substance P protects the brain after TBI in humans, these existing drugs could potentially be repurposed — a much faster path to treatment than developing entirely new drugs.

Read the original research

Tachykinin NK1 receptor antagonist L-733,060 and substance P deletion exert neuroprotection through inhibiting oxidative stress and cell death after traumatic brain injury in mice.

The international journal of biochemistry & cell biology, 107, 154-165

View on PubMed ↗Publisher’s paper ↗

Citation

Li, Qianqian; Wu, Xiao; Yang, Yanyan; Zhang, Yue; He, Fang; Xu, Xiang; Zhang, Ziwei; Tao, Luyang; Luo, Chengliang. (2019). Tachykinin NK1 receptor antagonist L-733,060 and substance P deletion exert neuroprotection through inhibiting oxidative stress and cell death after traumatic brain injury in mice.. The international journal of biochemistry & cell biology, 107, 154-165. https://doi.org/10.1016/j.biocel.2018.12.018